雷贝拉唑联合铝碳酸镁治疗胃食管反流病的疗效分析

目的评价雷贝拉唑联合铝碳酸镁治疗胃食管反流病的临床疗效。方法选取2010年8月至2013年10月收治的胃食管反流病患者40例，随机分为两组，其中观察组20例，采用雷贝拉唑联合铝碳酸镁治疗；对照组20例，采用奥美拉唑联合阿莫西林治疗。用药4周后观察并比较两组患者的反流症状改善程度和食管pH变化。结果观察组反流症状消失19例（95．0％），反流症状不消失1例（5．0％）；对照组反流症状消失14例（70．0％），反流症状不消失6例（30．0％），两组患者反流症状改善程度比较差异有统计学意义（P〈0．05）。食管pH〈4观察组2例（10．0％），对照组5例（25．0％）；食管pH〉4观察组18例（90．0％），对照组15例（75％），两组患者食管pH值变化比较差异有统计学意义（P〈0．05）。结论雷贝拉唑联合铝碳酸镁治疗胃食管反流病的临床疗效好，值得在临床上予以推广。

Analysis on treatment efficacy of hydrotalcid combined with rabeprazole in treating gastroesophsgeal reflux disease

Objective To evaluate the clinical efficacy of rabeprazole combined with aluminum magnesium in gastroesophageal reflux disease treatment. Methods From August 2010 to October 2013 in our hospital, 40 cases of gastroesophageal reflux disease were randomly divided into two groups, 20 cases in observation group, using aluminum magnesium rabeprazole combination therapy, the control group with 20 cases used omeprazole amoxicillin treatment, the degree of improvement in reflux symptoms and esophageal pH changes in two groups were compared after 4 weeks. Results The reflux symptoms disappeared in 19 patients （95%）, reflux symptoms did not disappear in 1 case （5%） in the control group reflux symptoms disappeared in 14 patients （70%）, reflux symptoms did not disappear in 6 patients （30%）, two reflux symptom improvement was statistically significantly different （P 〈 0.05）. In observation group 2 patients （10%） esophageal pH 〈 4, 18 patients （90%） esophageal pH 〉 4, the control group 5 cases （25%） esophageal pH 〈 4, 15 patients （75%） pH 〉 4, two esophagus pH changes showed statistical significant differences （P 〈 0.05）. Conclusion The combined aluminum magnesium rabeprazole therapy has good clinical efficacy in the treatment of gastroesophageal reflux disease, deserves to be promoted in clinical practice.